Angelman Biomarkers and Outcome Measures Alliance and Roche Begin Patient-Centered Qualitative Research to Inform Potential Outcome Measures for Angelman Syndrome Clinical Trials
The Angelman Biomarkers and Outcome Measures Alliance (A-BOM)A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has teamed up with F. Hoffmann-La Roche Ltd, (Roche), one of the world’s largest pharmaceutical and diagnostics companies, in the first phase of a study that will support the design of human clinical trials and treatment development for the disorder.